VcMMAE
|
|
|
- CAS-Nr.
- 646502-53-6
- Englisch Name:
- VcMMAE
- Synonyma:
- MC-VC-PAB-MMAE;MC-Val-Cit-PAB-MMAE;VeMMAE;VcMMAE;EOS-60990;VC-MMAE;VC MMAE;MC-VC-PABC-MMAE;MC-VAL-CIT-PABC-MMAE;VcMMAE (mc-vc-PAB-MMAE);Brentuximab Impurity 1 (Vedotin)
- CBNumber:
- CB22666699
- Summenformel:
- C68H105N11O15
- Molgewicht:
- 1316.63
- MOL-Datei:
- 646502-53-6.mol
|
VcMMAE Eigenschaften
- Siedepunkt:
- 1347.6±65.0 °C(Predicted)
- Dichte
- 1.196±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Room Temperature
- Löslichkeit
- Soluble in DMSO, DCM, DMF
- Aggregatzustand
- A solid
- pka
- 13.29±0.70(Predicted)
- InChIKey
- NLMBVBUNULOTNS-NNNQBTKHNA-N
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
VcMMAE Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
MC-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a thio reactive maleimidocaproyl (MC) group, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells.
Verwenden
Vedotin is an ultra-high-affinity small organic ligand of fibroblast activation protein used for tumor-targeting applications
Biologische Aktivität
VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). As a monoclonal antibody, it acts by binding to the extracellular domain of epidermal growth factor receptor (EGFR) and blocking its interaction with the ligands, thereby inhibiting cellular proliferation.
VcMMAE Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
VcMMAE Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 185)Lieferanten
- VcMMAE
- Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E
- 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
- MC-VC-PAB-MMAE,MC-Val-Cit-PAB-MMAE
- maleimido-caproyl-val-Cit-PAB-MMAE
- VeMMAE
- EOS-60990
- 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-Uriedidopenamiamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S),2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
- VC-MMAE;VC MMAE
- 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-((S)-2-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-y
- 4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-((S)-2-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methylbutanamido)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
- L-Valinamide, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-met...
- MC-VAL-CIT-PABC-MMAE
- Brentuximab Impurity 1 (Vedotin)
- [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
- VcMMAE (mc-vc-PAB-MMAE)
- Maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl monomethylauristatin E
- MC-Val-Cit-PAB-MMAE
- MC-VC-PAB-MMAE
- 4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
- VcMMAE(Synonyms: mc-vc-PAB-MMAE)
- [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o
- MC-VC-PABC-MMAE
- 646502-53-6
- 645602-53-6
- 646502-53-7
- 64650-53-6
- C68H105N11O15
- ADCs
- ADC
- ADC LINKER
- 646502-53-6
